KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2021 - 2023)

Ginkgo Bioworks Holdings' Long-Term Investments history spans 3 years, with the latest figure at $78.6 million for Q4 2023.

  • For Q4 2023, Long-Term Investments rose 4991.7% year-over-year to $78.6 million; the TTM value through Dec 2023 reached $78.6 million, up 4991.7%, while the annual FY2023 figure was $78.6 million, 4991.7% up from the prior year.
  • Long-Term Investments reached $78.6 million in Q4 2023 per DNA's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $121.8 million in Q1 2023 to a low of $37629.0 in Q2 2021.
  • Average Long-Term Investments over 3 years is $54.1 million, with a median of $47.5 million recorded in 2021.
  • The largest YoY upside for Long-Term Investments was 236600.42% in 2022 against a maximum downside of 98.49% in 2022.
  • A 3-year view of Long-Term Investments shows it stood at $102.0 million in 2021, then tumbled by 98.49% to $1.5 million in 2022, then soared by 4991.7% to $78.6 million in 2023.
  • Per Business Quant, the three most recent readings for DNA's Long-Term Investments are $78.6 million (Q4 2023), $1.1 million (Q3 2023), and $119.9 million (Q2 2023).